Abstract:Kaibo Hu, 1, 2, &ast Yanghuan Ou, 1, &ast Leyang Xiao, 1, 2, &ast Ruonan Gu, 1, 2 Fei He, 1, 2 Jie Peng, 1, 2 Yuan Shu, 1, 2 Ting Li, 1, 2 Liang Hao 1 1 Department of Orthopedics, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, People's Republic of China; 2 The Second Clinical Medical College, Nanchang University, Nanchang, 330006, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liang Hao, Tel +86 136 0700 8562, Email Background: Osteoarthritis (OA) is a major cause of human disability. Despite receiving treatment, patients with the middle and late stage of OA have poor survival outcomes. Therefore, within the framework of predictive, preventive, and personalized medicine (PPPM/3PM), early personalized diagnosis of OA is particularly prominent. PPPM aims to accurately identify disease by integrating multiple omic techniques; however, the efficiency of currently available methods and biomarkers in predicting and diagnosing OA should be improved. Disulfidptosis, a novel programmed cell death mechanism and appeared in particular metabolic status, plays a mysterious characteristic in the occurrence and development of OA, which warrants further investigation. Methods: In this study, we integrated three public datasets from the Gene Expression Omnibus (GEO) database, including 26 OA samples and 20 normal samples. Via a series of bioinformatic analysis and machine learning, we identified the diagnostic biomarkers and several subtypes of OA. Moreover, the expression of these biomarkers were verified in our in-house cohort and the single cell dataset. Results: Three significant regulators of disulfidptosis (NCKAP1, OXSM, and SLC3A2) were identified through differential expression analysis and machine learning. And a nomogram constructed based on these three regulators exhibited ideal efficiency in predicting early- and late-stage OA. Furthermore, based on the expression of three regulators, we identified two disulfidptosis-related subtypes of OA with different infiltration of immune cells and personalized expression level of immune checkpoints. Notably, the expression of the three regulators was demonstrated in a single-cell RNA profile and verified in the synovial tissue in our in-house cohort including 6 OA patients and 6 normal people. Finally, an efficient disulfidptosis-mediated diagnostic model was constructed for OA, with the AUC value of 97.6923% in the training set and 93.3333% and 100% in two validation sets. Conclusion: Overall, with regard to PPPM, this study provided novel insights into the role of disulfidptosis regulators in the personalized diagnosis and treatment of OA. Keywords: osteoarthritis, disulfidptosis, perspective of predictive, preventive and personalized medicine, immune microenvironment, diagnostic model Osteoarthritis (OA) is a multifaceted degenerative disease that involves both inflammatory and metabolic factors. It is one of the common joint diseases that mostly affects the knees, hands, feet, hips and spine. 1 OA is more prevalent in women, the elderly population and patients with obesity. According to the recent statistical data reported by the World Health Organization (WHO), the prevalence of OA has increased from 12.3% to 21.6%. 2,3 The quality of life and motor functions of patients with end-stage OA are substantially deteriorated, which is a leading cause of disability and an important health concern worldwide. 4 Moreover, early diagnosis of OA remains a major challenge for clinicians. 5 Therefore, early and personalized detection, diagnosis, intervention and treatment are particularly crucial. With the development of modern medicine, predictive, preventive and personalized medicine (PPPM) has exhibited a thriving trend for future medical strategies. PPPM aims to continuously integrate the development trends of contemporary biomedical technology to provide novel insights into the early detection, diagnosis and treatment of diseases. 6,7 Unlike previous medical models, PPPM is committed to taking action before or in the early stages of a disease to suppress its occurrence and development. 8 At present, PPPM is used for the monitoring, prevention and early diagnosis of various diseases, especially some degenerative and chronic diseases. 7 Although the concepts of primary, secondary and tertiary prevention apply to the management of OA, the application of the PPPM framework is significantly limited in OA compared with cancer, di -Abstract Truncated-

Disease progression and clinical outcomes in latent osteoarthritis phenotypes: Data from the Osteoarthritis Initiative

Disease progression and clinical outcomes in latent osteoarthritis phenotypes: Data from the Osteoarthritis Initiative

A clinical model to predict the progression of knee osteoarthritis: data from Dryad

Phenotypes of osteoarthritis-related knee pain and their transition over time: data from the osteoarthritis initiative

Identifying Robust Risk Factors for Knee Osteoarthritis Progression: An Evolutionary Machine Learning Approach

Predicting rapid progression in knee osteoarthritis: a novel and interpretable automated machine learning approach, with specific focus on young patients and early disease

Multimodal Machine Learning-based Knee Osteoarthritis Progression Prediction from Plain Radiographs and Clinical Data

Predicting the onset of end-stage knee osteoarthritis over two- and five-years using machine learning

Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning

A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening

Identifying the Phenotypic and Temporal Heterogeneity of Knee Osteoarthritis: Data From the Osteoarthritis Initiative

Identification of Biomarkers Associated with Diagnosis of Osteoarthritis Patients Based on Bioinformatics and Machine Learning

Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data

Insights into osteoarthritis progression revealed by analyses of both knee tibiofemoral compartments

Osteoarthritis endotype discovery via clustering of biochemical marker data

Characterization of clinical data for patient stratification in moderate osteoarthritis with support vector machines, regulatory network models, and verification against osteoarthritis Initiative data

Identification and experimental validation of key genes in osteoarthritis based on machine learning algorithms and single-cell sequencing analysis

Development and validation of a machine learning-supported strategy of patient selection for osteoarthritis clinical trials: the IMI-APPROACH study

Characterizing Osteophyte Formation in Knee Osteoarthritis: Application of Machine Learning Quantification of a Computerized Tomography Cohort: Implications for Treatment

Identification and Construction of a Disulfidptosis-Mediated Diagnostic Model and Associated Immune Microenvironment of Osteoarthritis from the Perspective of PPPM

Prognostic Models for Knee Osteoarthritis: a Protocol for Systematic Review, Critical Appraisal, and Meta-Analysis